Mental health not a high enough priority for NHS vanguards, says King’s Fund
News
Biogen pays $120 million for late-stage stroke treatment Cirara
Strikes licensing deal with Remedy Pharmaceuticals
Sobi named UK’s top haemophilia company
Tops IPC Associates’ 2016 ranking
FDA to fast-track Pfizer/Sangamo gene therapy orphan drug
SB-525 is being developed to treat haemophilia A
Aspen Pharmacare hit by EU antitrust cancer drug price probe
European regulators will investigate pricing of five oncology treatments
NHS could save £67 million a year if smoking rates cut
But would need rates to drop to 5 percent
ReNeuron wins £1.8 million for cell therapy development
Innovate UK grant will help advance its manufacturing capabilities
Takeda establishes new drug discovery subsidiary
Also transfers part of its pharmaceutical sciences businesses to Bushu
Triple trial boost for Lilly’s migraine drug
CGRP treatment galcanezumab looks to be course for regulatory submissions
NHS cyber attack – fallout continues
Cancellations and slower health services after 48 NHS Trusts hit by ransomware
NHS Confederation calls on government for health funding plan
The body presents case for 10 ‘asks’ before the snap election
Pfizer strikes gene therapy deal with Sangamo
Says one of the candidates included has best-in-class potential
Hepatitis C infections nearly tripled over five years
Number of reported infections reaches 15-year high
UK patients get early access to AbbVie’s hepatitis regimen
AbbVie’s glecaprevir/pibrentasvir (G/P) has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme (EAMS).
Accelerated approval for Keytruda as combo for NSCLC
The US Food and Drug Administration has issued an accelerated approval for Merck & Co’s immunotherapy Keytruda in combination with pemetrexed (Eli Lilly’s Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
